Halozyme Therapeutics reported $75.67M in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
DBV Technologies DBVT:US -16771000 2.37M
Acadia Pharmaceuticals ACAD:US $ -113016000 68.36M
Agios Pharmaceuticals AGIO:US $ -101145000 3.68M
Alnylam Pharmaceuticals ALNY:US $ -146732000 47.83M
Amarin AMRN:US -28307000 44.04M
Amgen AMGN:US $ 2500M 196M
Aptinyx Inc APTX:US $ -19379000 207K
Baxter International BAX:US $ 531M 108M
Cara Therapeutics CARA:US $ -27911000 5.61M
Cytokinetics CYTK:US $ -77857000 58.95M
Esperion Therapeutics ESPR:US $ -42989000 611K
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Immunogen IMGN:US $ -22852000 11.7M
Intrexon XON:US $ -17414000 3.07M
IONIS PHARMACEUT IONS:US $ -57504000 278.11M
JAZZ PHA JAZZ:US 87.55M 105.43M
Minerva Neurosciences NERV:US $ -7989260 13.39M
Nektar Therapeutics NKTR:US $ -112910000 686K
Peregrine Pharmaceuticals PPHM:US $ 3.27M 884K
United Therapeutics UTHR:US $ 288M 117.2M
Vanda Pharmaceuticals VNDA:US $ -7669000 36.1M